<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474644</article-id><article-id pub-id-type="pmcid-ver">PMC12474644.1</article-id><article-id pub-id-type="pmcaid">12474644</article-id><article-id pub-id-type="pmcaiid">12474644</article-id><article-id pub-id-type="pmid">40768190</article-id><article-id pub-id-type="doi">10.1007/s12325-025-03308-2</article-id><article-id pub-id-type="publisher-id">3308</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician&#8217;s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0275-2575</contrib-id><name name-style="western"><surname>Touzeau</surname><given-names initials="C">Cyrille</given-names></name><address><email>Cyrille.TOUZEAU@chu-nantes.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lipe</surname><given-names initials="B">Brea</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="AM">Abdullah M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhakal</surname><given-names initials="B">Binod</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nair</surname><given-names initials="S">Sandhya</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="J">Jianming</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mendes</surname><given-names initials="J">Jo&#227;o</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="S">Seina</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lonardi</surname><given-names initials="C">Carolina</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Slaughter</surname><given-names initials="A">Ana</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lendvai</surname><given-names initials="N">Nikoletta</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schecter</surname><given-names initials="JM">Jordan M.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="D">Diana</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="M">Man</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yeh</surname><given-names initials="TM">Tzu-min</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leleu</surname><given-names initials="X">Xavier</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Puig</surname><given-names initials="N">Noem&#237;</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dytfeld</surname><given-names initials="D">Dominik</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zamagni</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weisel</surname><given-names initials="K">Katja</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karlin</surname><given-names initials="L">Lionel</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Delforge</surname><given-names initials="M">Michel</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Corradini</surname><given-names initials="P">Paolo</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mina</surname><given-names initials="R">Roberto</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roeloffzen</surname><given-names initials="W">Wilfried</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sidana</surname><given-names initials="S">Surbhi</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03gnr7b55</institution-id><institution-id institution-id-type="GRID">grid.4817.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 0784</institution-id><institution>Service d&#8217;H&#233;matologie, </institution><institution>Centre Hospitalier Universitaire de Nantes, Nantes Universit&#233;, </institution></institution-wrap>5 All. de l&#8217;&#206;le Gloriette, 44000 Nantes, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03gnr7b55</institution-id><institution-id institution-id-type="GRID">grid.4817.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 0784</institution-id><institution>Centre de Recherche en Canc&#233;rologie et Immunologie Int&#233;gr&#233;e Nantes Angers, </institution><institution>INSERM, Centre National de la Recherche Scientifique, Universit&#233; d&#8217;Angers, Universit&#233; de Nantes, </institution></institution-wrap>Nantes, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03m8vkq32</institution-id><institution-id institution-id-type="GRID">grid.455095.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 059X</institution-id><institution>Site de Recherche Int&#233;gr&#233;e sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-Making (ILIAD), </institution><institution>French National Cancer Institute&#8211;French Ministry of Health&#8211;INSERM, </institution></institution-wrap>12558, Nantes, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00trqv719</institution-id><institution-id institution-id-type="GRID">grid.412750.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9166</institution-id><institution>University of Rochester Medical Center, </institution></institution-wrap>Rochester, NY USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/028t46f04</institution-id><institution-id institution-id-type="GRID">grid.413944.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0447 4797</institution-id><institution>The Ohio State University Comprehensive Cancer Center, </institution></institution-wrap>Columbus, OH USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00qqv6244</institution-id><institution-id institution-id-type="GRID">grid.30760.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2111 8460</institution-id><institution>Medical College of Wisconsin, </institution></institution-wrap>Milwaukee, WI USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04yzcpd71</institution-id><institution-id institution-id-type="GRID">grid.419619.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 0341</institution-id><institution>Johnson &amp; Johnson, </institution></institution-wrap>Beerse, Belgium </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qd7mz70</institution-id><institution-id institution-id-type="GRID">grid.417429.d</institution-id><institution>Johnson &amp; Johnson, </institution></institution-wrap>Raritan, NJ USA </aff><aff id="Aff9"><label>9</label>Johnson &amp; Johnson, Buenos Aires, Argentina </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00505z102</institution-id><institution-id institution-id-type="GRID">grid.470133.2</institution-id><institution>Johnson &amp; Johnson, </institution></institution-wrap>Zug, Switzerland </aff><aff id="Aff11"><label>11</label>Johnson &amp; Johnson, Shanghai, China </aff><aff id="Aff12"><label>12</label>IQVIA, Shanghai, China </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/029s6hd13</institution-id><institution-id institution-id-type="GRID">grid.411162.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9336 4276</institution-id><institution>CHU Poitiers, </institution></institution-wrap>Poitiers, France </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03em6xj44</institution-id><institution-id institution-id-type="GRID">grid.452531.4</institution-id><institution>Centro de Investigaci&#243;n del Cancer, </institution><institution>Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, </institution></institution-wrap>Salamanca, Spain </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02zbb2597</institution-id><institution-id institution-id-type="GRID">grid.22254.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2205 0971</institution-id><institution>Poznan University of Medical Sciences, </institution></institution-wrap>Pozna&#324;, Poland </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01111rn36</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution>University of Bologna, </institution></institution-wrap>Bologna, Italy </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/023xgd207</institution-id><institution-id institution-id-type="GRID">grid.411430.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0288 2594</institution-id><institution>H&#244;pital Lyon Sud, Hospices Civils de Lyon, </institution></institution-wrap>Pierre-B&#233;nite, France </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05f950310</institution-id><institution-id institution-id-type="GRID">grid.5596.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 7884</institution-id><institution>University of Leuven, </institution></institution-wrap>Leuven, Belgium </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05dwj7825</institution-id><institution-id institution-id-type="GRID">grid.417893.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 2568</institution-id><institution>Divisione di Ematologia, </institution><institution>Fondazione IRCCS Istituto Nazionale dei Tumori, Universit&#224; di Milano, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048tbm396</institution-id><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>The Division of Hematology, AOU Citt. della Salute e della Scienza di Torino, and the Department of Molecular Biotechnology and Health Sciences, </institution><institution>University of Turin, </institution></institution-wrap>Turin, Italy </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cv38k47</institution-id><institution-id institution-id-type="GRID">grid.4494.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 4598</institution-id><institution>University Medical Center Groningen, </institution></institution-wrap>Groningen, Netherlands </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Stanford University School of Medicine, </institution></institution-wrap>Stanford, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>42</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><fpage>5023</fpage><lpage>5041</lpage><history><date date-type="received"><day>8</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 13:25:37.627"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12325_2025_Article_3308.pdf"/><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04181827">NCT04181827</ext-link>), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1&#8211;3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician&#8217;s choice of treatment for lenalidomide-refractory MM.</p></sec><sec><title>Methods</title><p id="Par2">De-identified data from the Flatiron Health MM cohort registry (January 2020 to May&#160;2024) were compared with data from CARTITUDE-4 (data cutoff May&#160;1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the Flatiron database. Baseline covariates of prognostic significance were adjusted using inverse probability of treatment weighting. Outcomes for comparative effectiveness included progression-free survival (PFS), RW PFS, time to next treatment (TTNT), and overall survival (OS). Sensitivity analyses were conducted.</p></sec><sec><title>Results</title><p id="Par3">The CARTITUDE-4 cohort included data from 208 patients who received cilta-cel; the median follow-up was 33.6&#160;months. The real-world cohort included 932 patients (1445 eligible LOT) from the Flatiron database; the median follow-up was 23.6&#160;months. In base case analyses, compared with the Flatiron cohort, patients treated with cilta-cel had improved PFS (hazard ratio [HR] 0.29 [95% confidence interval (CI)] 0.22&#8211;0.36; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), RW-PFS (HR 0.29 [95%&#160;CI 0.23&#8211;0.37]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), TTNT (HR 0.32 [95%&#160;CI 0.25&#8211;0.41]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and OS (HR 0.59 [95%&#160;CI 0.41&#8211;0.84]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003). These findings were consistent across all sensitivity analyses.</p></sec><sec><title>Conclusion</title><p id="Par4">Cilta-cel lengthened TTNT and demonstrated meaningful prolongation in PFS and OS compared with real-world physician&#8217;s choice for lenalidomide-refractory MM. These data highlight the value of cilta-cel as an effective therapy in earlier-line patients with relapsed, lenalidomide-refractory MM exposed to proteasome inhibitors and immunomodulatory drugs.</p></sec><sec><title>Trial registration</title><p id="Par5">CARTITUDE-4: ClinicalTrials.gov ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04181827">NCT04181827</ext-link>.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12325-025-03308-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ciltacabtagene autoleucel</kwd><kwd>Flatiron health database</kwd><kwd>Relapsed or refractory multiple myeloma</kwd><kwd>CARTITUDE-4</kwd><kwd>Real-world data</kwd><kwd>Indirect treatment comparison</kwd><kwd>CAR-T</kwd></kwd-group><funding-group><award-group><funding-source><institution>Johnson &amp; Johnson</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Healthcare Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e557"><title>Key Summary Points</title><p id="Par6">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">Why carry out this study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Indirect treatment comparisons (ITCs) can be used to assess the benefits of treatments used in clinical trials relative to those used in clinical practice in the absence of head-to-head comparisons.</td></tr><tr><td align="left" colspan="1" rowspan="1">Data from head-to-head comparisons for ciltacabtagene autoleucel (cilta-cel) versus established standard of care regimens used in real-world clinical practice for the treatment of lenalidomide-refractory multiple myeloma (MM) after 1&#8211;3 prior lines of therapy are lacking.</td></tr><tr><td align="left" colspan="1" rowspan="1">This ITC evaluated the relative efficacy of cilta-cel using data from the CARTITUDE-4 data versus standard-of-care real-world physician&#8217;s choice of therapies from the Flatiron registry.</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">What was learned from this study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Cilta-cel prolonged the time to next antimyeloma treatment and reduced the risk of disease progression or death compared with real-world physician&#8217;s choice for lenalidomide-refractory MM.</td></tr><tr><td align="left" colspan="1" rowspan="1">These data demonstrate that cilta-cel is an effective therapy in patients with relapsed or refractory MM who have received at least one prior line of therapy and are lenalidomide-refractory.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par7">Therapeutic advances including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies have improved patient outcomes. However, multiple myeloma (MM) remains incurable [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Additionally, most patients with MM will relapse on these standard therapies and have worse outcomes with each subsequent line of therapy (LOT) [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Lenalidomide, an IMiD, is recommended across all lines of MM therapy, including newly diagnosed and relapsed or refractory MM (RRMM) [<xref ref-type="bibr" rid="CR13">13</xref>], but resistance has been reported [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], highlighting the need for additional effective therapies.</p><p id="Par8">Currently, combination therapies of daratumumab, an anti-CD38 monoclonal antibody, with pomalidomide (IMiD) plus dexamethasone (DPd), and daratumumab with carfilzomib (PI) plus dexamethasone (DKd), as well as pomalidomide with bortezomib (PV) plus dexamethasone (PVd) are preferred regimens for the treatment of lenalidomide-refractory MM after 1&#8211;3 prior LOT, based on National Comprehensive Cancer Network (NCCN), International Myeloma Working Group (IMWG), and European Society for Medical Oncology (ESMO) guidelines [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par9">Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T&#160;cell (CAR-T) therapy directed against B&#160;cell maturation antigen, demonstrated superior efficacy and a manageable safety profile versus physician&#8217;s choice of standard care (PVd or DPd) in patients with lenalidomide-refractory MM after 1&#8211;3 prior LOT in the randomized, phase&#160;3 CARTITUDE-4 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04181827">NCT04181827</ext-link>) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. At 33.6-month median follow-up, overall survival (OS) significantly improved in the cilta-cel group versus the standard-care group. Median OS was not reached in the cilta-cel group (95% confidence interval [CI] not estimable) or standard-care group (95%&#160;CI 37.75&#160;months to not estimable; hazard ratio [HR], 0.55 [95%&#160;CI 0.39&#8211;0.79]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.0009); 30-month OS rates were 76.4% and 63.8%, respectively. Additionally, median progression-free survival (PFS) was not reached (95%&#160;CI 34.50&#160;months to not estimable) in the cilta-cel group and was 11.79&#160;months (95%&#160;CI 9.66&#8211;14.00) in the standard-care group (HR for progression or death, 0.29 [95%&#160;CI 0.22&#8211;0.39], protocol-specified weighted analysis); 30-month PFS rates were 59.4% and 25.7%, respectively. Adverse events (AEs) were consistent with the known safety profile of cilta-cel [<xref ref-type="bibr" rid="CR20">20</xref>]. No new safety signals, including movement and neurocognitive AEs or cranial nerve palsy, were observed after an additional 17.7&#160;months of follow-up [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par10">Although DPd and PVd are established regimens for the treatment of lenalidomide-refractory MM after 1&#8211;3 prior LOT, the treatment choices are not exclusively restricted to these regimens [<xref ref-type="bibr" rid="CR21">21</xref>]. Additionally, availability and access to these therapies varies worldwide; therefore, it is important to generate results comparing cilta-cel with standard-care regimens used in real-world (RW) clinical practice settings. Indirect treatment comparisons (ITCs) can be used to assess the benefits of treatments used in clinical trials relative to those used in clinical practice in the absence of head-to-head comparisons [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. ITC methods allow for creation of an external, RW control arm representing patients who would have been randomized to physician&#8217;s choice of treatment. This RW cohort can be compared with the cilta-cel cohort in CARTITUDE-4.</p><p id="Par11">In this study, we performed an ITC to evaluate the comparative effectiveness of cilta-cel in CARTITUDE-4 and RW physician&#8217;s choice of treatment from the Flatiron Health database in patients with lenalidomide-refractory MM after 1&#8211;3 prior LOT.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Data Source</title><p id="Par12">CARTITUDE-4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04181827">NCT04181827</ext-link>) is a phase&#160;3, randomized, open-label trial assessing the efficacy and safety of cilta-cel versus RW physician&#8217;s choice of effective standard care in patients with lenalidomide-refractory MM after 1&#8211;3 LOT, including a PI and an IMiD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Patient recruitment included 81 sites in the USA, Europe, Asia, and Australia. No information was available whether a patient enrolled was also included in the Flatiron database. The primary endpoint was PFS, which was defined as the time from randomization to the first documentation of disease progression or death. Secondary endpoints included rate of complete response or better, overall response rates, minimal residual disease negativity, OS, AEs, pharmacokinetics and worsening of patient-reported symptoms as assessed by the Multiple Myeloma Symptom and Impact Questionnaire. Treatment responses and disease progression were determined according to the International Myeloma Working Group (IMWG) criteria. Time to next treatment (TTNT) was also assessed.</p><p id="Par13">CARTITUDE-4 was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. The independent ethics committee or institutional review board at each site approved the protocol (Supplemental Table&#160;<xref rid="MOESM1" ref-type="media">S1</xref>). All patients provided written informed consent.</p><p id="Par14">Flatiron Health&#8217;s longitudinal database consists of de-identified patient-level electronic health record (EHR) data primarily from US community-based oncology clinics but also academic centers. The database includes an MM cohort registry from over 280 cancer clinics [<xref ref-type="bibr" rid="CR25">25</xref>]. Flatiron Health leverages this database to develop RW data offerings on a tumor-by-tumor type basis. The Flatiron Health MM dataset includes diagnostic and treatment details captured during routine clinical care, either as structured data (e.g., International Classification of Diseases, 9th and 10th Revisions codes, laboratory values [e.g., M-protein level], medication orders, and medication administrations) or unstructured data (e.g., abstracted data obtained from EHR documents, including confirmed diagnosis, fluorescence in situ hybridization cytogenetics and karyotyping at diagnosis, and stem cell transplant). Additional derived variables include LOT and International Staging System (ISS) stage at time of diagnosis.</p></sec><sec id="Sec4"><title>Patient Population</title><p id="Par15">Individual patient data from CARTITUDE-4 (enrollment 10 July 2020 through 17 November 2021; data cutoff for this analysis was May&#160;1, 2024) and de-identified EHR data derived from the Flatiron Health MM cohort registry between January 2020 and May&#160;2024 were used to conduct adjusted comparisons between cilta-cel and RW treatment. The timeframe of the RW cohort was chosen to align with enrollment in CARTITUDE-4 and to better represent the current treatment landscape in MM.</p><p id="Par16">Data from patients in the cilta-cel cohort from the CARTITUDE-4 study were compared with patients from the de-identified Flatiron database who met key CARTITUDE-4 eligibility criteria (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). All patients had lenalidomide-refractory MM after 1&#8211;3 LOT, including a PI and an IMiD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Refractory MM was defined as nonresponsive disease (i.e., not achieving minimal response or disease progression on therapy) with primary or salvage therapy, or disease progression within 60&#160;days of last therapy [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Patient selection procedure. <italic toggle="yes">BCMA</italic> B&#160;cell maturation antigen, <italic toggle="yes">CAR-T</italic> chimeric antigen receptor T&#160;cell, <italic toggle="yes">ECOG PS</italic>, Eastern Cooperative Oncology Group performance score, <italic toggle="yes">IMiD</italic> immunomodulatory drug, <italic toggle="yes">MM</italic> multiple myeloma, <italic toggle="yes">PI</italic> proteasome inhibitor, <italic toggle="yes">RW</italic> real-world</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12325_2025_3308_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Outcomes</title><p id="Par17">Comparative effectiveness analyses included the intent-to-treat population from the CARTITUDE-4 cilta-cel cohort and all eligible patients from the RW physician&#8217;s choice of treatment cohort.</p><p id="Par18">Comparative effectiveness of cilta-cel versus RW treatment was assessed by PFS, real-world PFS (RW-PFS), TTNT, and OS. Safety was not in the scope of this analysis. PFS was defined as the duration from the index date to the date of disease progression or death due to any cause, whichever occurred first. Disease progression was evaluated per IMWG criteria. For patients who had not progressed and were alive at the time of the data cutoff, data were censored at the last disease evaluation before the start of any subsequent antimyeloma therapy. PFS in the RW cohort may be underestimated as disease progression was measured by M-protein and serum-free light chain only; other measurements such as bone marrow or bone lesion assessments were lacking. Therefore, RW-PFS was assessed for both cohorts in this study. RW-PFS was defined as the duration from the index date to the date of next antimyeloma treatment, disease progression, or death, whichever comes first. For patients who had not developed any of these events, data were censored at the last disease evaluation. TTNT was defined as the time from index date to the initiation date of next antimyeloma treatment or death, whichever occurred first. Patients who were still alive and did not initiate a new LOT at the data cutoff were censored at the last date known to be alive. OS was defined as the time from the index date to the date of death. Patients who were still alive at the data cutoff were censored at the last date known to be alive. The index date (time&#160;0) in CARTITUDE-4 for all outcomes was the date of randomization; the index date in the RW cohort was defined as the date when patients met inclusion criteria.</p></sec><sec id="Sec6"><title>Statistical Analyses</title><p id="Par19">To account for imbalances in baseline patient characteristics between the CARTITUDE-4 and RW cohorts, inverse probability of treatment weighting (IPTW) with average treatment effects in the treated derived from propensity scores was performed to ensure that patients in the RW cohort resembled patients in CARTITUDE-4. IPTW uses a balancing score to derive weights for the desired target population, which minimizes confounding and removes potential effect modifiers. To identify and rank prognostic factors that might influence effectiveness estimates, a clinician-driven process was used. A list of potential factors was identified a priori by consulting studies from a literature review conducted to identify clinical outcomes in patients with triple-class-exposed RRMM and was presented to a panel of clinical experts [<xref ref-type="bibr" rid="CR24">24</xref>]. Among 15 prognostic factors, the panel prioritized five: refractory status, cytogenetic profile, ISS stage, time to progression on last regimen, and total plasmacytoma (extramedullary plasmacytomas and soft-tissue components of bone-based plasmacytomas [<xref ref-type="bibr" rid="CR24">24</xref>]). Total plasmacytoma was not available from the Flatiron Health database and therefore was not included. Additional prognostic variables identified by the panel that were considered key covariates for the IPTW analyses were number of prior LOT, years since MM diagnosis, age, hemoglobin, and lactate dehydrogenase (LDH) levels. LDH levels were also excluded because of missingness in the Flatiron Health database, resulting in eight top-ranked variables utilized in the base case analysis: refractory status, time to progression on the last regimen, cytogenetic profile, ISS stage, number of prior LOT, years since MM diagnosis, age, and hemoglobin. Prior stem cell transplant, Eastern Cooperative Oncology Group performance status (ECOG PS), race, sex, and type of MM were also identified by the panel as key factors and, in addition to the eight variables in the base case analysis, were adjusted for in a sensitivity analysis (&#8220;fully adjusted analysis&#8221;). Population differences between CARTITUDE-4 and the RW cohort were assessed using standardized mean differences (SMDs) (small, 0 to 0.1; moderate, &gt;&#8201;0.1 to &#8804;&#8201;0.2; substantial, &gt;&#8201;0.2) [<xref ref-type="bibr" rid="CR28">28</xref>]. For both the CARTITUDE-4 and RW cohorts, no imputation was conducted for the missing cytogenetic data and was thus treated as a separate category; however, the actual distribution of high versus standard cytogenetic risk in each database may differ. For the RW cohort, variables with missing values (ISS stage, hemoglobin, and ECOG PS) were imputed using the last observation prior to the index date.</p><p id="Par20">Estimates of comparative effectiveness were derived for both the unadjusted (cilta-cel vs RW physician&#8217;s choice of treatment prior to IPTW) and the adjusted comparison (IPTW). Treatment effect estimates, effective sample size, and covariate balance are reported for both scenarios. Sensitivity analyses evaluated the impact of alternative statistical methods and variable adjustment and were conducted using the multivariate regression and doubly robust methods [<xref ref-type="bibr" rid="CR29">29</xref>]. First patient case weighting (i.e., the first LOT satisfying the inclusion criteria and not including patients with multiple eligible LOT) was also conducted as a sensitivity analysis. Transformations and interaction terms were not included.</p><p id="Par21">For time-to-event outcomes, a weighted Cox proportional hazards model was used to derive a HR and its respective 95%&#160;CI. A weighted Kaplan&#8211;Meier method was used to derive the median time to event, each with its respective 95%&#160;CI. To account for patients with multiple index dates, the variance was estimated using a robust sandwich variance estimator specifying the patient identifier.</p><p id="Par22">A significance level of 0.05 was used for all comparisons, without adjustment for multiplicity. All statistical analyses were performed with R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Selection of Patients</title><p id="Par23">The CARTITUDE-4 cohort included data from 208 patients randomized to the cilta-cel arm, with a median follow-up of 33.6&#160;months (data cutoff May&#160;1, 2024). The RW cohort included 932 patients from the de-identified Flatiron database, contributing 1445 eligible LOT between January 2020 and May&#160;2024. Median follow-up was 23.6&#160;months.</p><p id="Par24">Overall and RW cohort weight distributions are shown in Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">S2</xref>. Before reweighting, substantial differences (SMD&#8201;&gt;&#8201;0.20) between the CARTITUDE-4 and RW cohorts were observed for several of the baseline characteristic variables. More patients in the CARTITUDE-4 cohort had high-risk cytogenetics (59.4% vs 37.8%), defined as del17p, t[4;14], t[14;16], or gain/amp[1q] for both cohorts [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]), progressed on their last LOT&#8201;&gt;&#8201;16&#160;months before the index treatment (51.0% vs 24.5%), had an MM diagnosis&#8201;&#8805;&#8201;3&#160;years before the index treatment (50.0% vs 34.3%), and had a prior stem cell transplant (82.2% vs 30.2%). In contrast, the RW cohort had a greater proportion of patients with ISS Stage&#160;III disease (5.8% vs 16.8%), who were&#8201;&#8805;&#8201;65&#160;years of age (39.4% vs 66.0%), and were refractory to a PI (49.5% vs 71.6%) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Group demographic balance before and after IPTW weighting for the comparison of the CARTITUDE-4 cilta-cel and RW cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="left" rowspan="2" colspan="1">CARTITUDE-4 cilta-cel cohort<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;208)</th><th align="left" colspan="2" rowspan="1">Observed (before weighting)</th><th align="left" colspan="2" rowspan="1">Base case (weighted)</th><th align="left" colspan="2" rowspan="1">Base case fully adjusted (weighted)</th></tr><tr><th align="left" colspan="1" rowspan="1">RW cohort<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;1445<sup>a</sup>)</th><th align="left" colspan="1" rowspan="1">SMD</th><th align="left" colspan="1" rowspan="1">RW cohort ESS<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;463<sup>b</sup>)</th><th align="left" colspan="1" rowspan="1">SMD</th><th align="left" colspan="1" rowspan="1">RW cohort ESS<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;249<sup>b</sup>)</th><th align="left" colspan="1" rowspan="1">SMD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Refractory to PI, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">103 (49.5)</td><td align="left" colspan="1" rowspan="1">1035 (71.6)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.46</td><td align="left" colspan="1" rowspan="1">108 (54.6)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.11</td><td align="left" colspan="1" rowspan="1">108 (55.8)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">Refractory to anti-CD38, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">50 (24.0)</td><td align="left" colspan="1" rowspan="1">371 (25.7)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.04</td><td align="left" colspan="1" rowspan="1">54 (27.0)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.07</td><td align="left" colspan="1" rowspan="1">53 (27.5)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Progression on the last LOT&#8201;&gt;&#8201;16&#160;months before the index treatment, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">106 (51.0)</td><td align="left" colspan="1" rowspan="1">354 (24.5)</td><td align="left" colspan="1" rowspan="1">0.57</td><td align="left" colspan="1" rowspan="1">94 (47.3)</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">87 (44.9)</td><td char="." align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="8" rowspan="1">Cytogenetic risk category, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High-risk<sup>c</sup></td><td align="left" colspan="1" rowspan="1">123 (59.1)</td><td align="left" colspan="1" rowspan="1">546 (37.8)</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">114 (57.3)</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1">109 (56.5)</td><td char="." align="char" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Standard-risk</td><td align="left" colspan="1" rowspan="1">69 (33.2)</td><td align="left" colspan="1" rowspan="1">616 (42.6)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.20</td><td align="left" colspan="1" rowspan="1">68 (34.3)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.02</td><td align="left" colspan="1" rowspan="1">68 (35.3)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">16 (7.7)</td><td align="left" colspan="1" rowspan="1">283 (19.6)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.35</td><td align="left" colspan="1" rowspan="1">17 (8.4)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.02</td><td align="left" colspan="1" rowspan="1">16 (8.2)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="8" rowspan="1">ISS stage, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I</td><td align="left" colspan="1" rowspan="1">136 (65.4)</td><td align="left" colspan="1" rowspan="1">843 (58.3)</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">131 (65.7)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">124 (64.3)</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;II</td><td align="left" colspan="1" rowspan="1">60 (28.8)</td><td align="left" colspan="1" rowspan="1">359 (24.8)</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">56 (28.1)</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">57 (29.4)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;III</td><td align="left" colspan="1" rowspan="1">12 (5.8)</td><td align="left" colspan="1" rowspan="1">243 (16.8)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.35</td><td align="left" colspan="1" rowspan="1">12 (6.2)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">12 (6.3)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="8" rowspan="1">Prior lines of treatments, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1</td><td align="left" colspan="1" rowspan="1">68 (32.7)</td><td align="left" colspan="1" rowspan="1">390 (27.0)</td><td align="left" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1">56 (28.3)</td><td align="left" colspan="1" rowspan="1">0.10</td><td align="left" colspan="1" rowspan="1">51 (26.7)</td><td char="." align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;2</td><td align="left" colspan="1" rowspan="1">83 (39.9)</td><td align="left" colspan="1" rowspan="1">538 (37.2)</td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">84 (42.3)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.05</td><td align="left" colspan="1" rowspan="1">88 (45.8)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;3</td><td align="left" colspan="1" rowspan="1">57 (27.4)</td><td align="left" colspan="1" rowspan="1">517 (35.8)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.18</td><td align="left" colspan="1" rowspan="1">58 (29.4)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.04</td><td align="left" colspan="1" rowspan="1">53 (27.5)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Time from MM diagnosis to index treatment&#8201;&#8805;&#8201;3&#160;years, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">104 (50.0)</td><td align="left" colspan="1" rowspan="1">495 (34.3)</td><td align="left" colspan="1" rowspan="1">0.32</td><td align="left" colspan="1" rowspan="1">105 (52.7)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.06</td><td align="left" colspan="1" rowspan="1">97 (50.1)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Age&#8201;&#8805;&#8201;65&#160;years, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">82 (39.4)</td><td align="left" colspan="1" rowspan="1">954 (66.0)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.55</td><td align="left" colspan="1" rowspan="1">82 (41.1)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">78 (40.7)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hemoglobin category&#8201;&#8805;&#8201;12, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">78 (37.5)</td><td align="left" colspan="1" rowspan="1">664 (46.0)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.17</td><td align="left" colspan="1" rowspan="1">74 (37.2)</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">72 (37.4)</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Prior transplant, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">171 (82.2)</td><td align="left" colspan="1" rowspan="1">437 (30.2)</td><td align="left" colspan="1" rowspan="1">1.23</td><td align="left" colspan="1" rowspan="1">83 (41.7)</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">155 (80.3)</td><td char="." align="char" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ECOG PS score 1, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">94 (45.2)</td><td align="left" colspan="1" rowspan="1">854 (59.1)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.28</td><td align="left" colspan="1" rowspan="1">105 (52.8)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.15</td><td align="left" colspan="1" rowspan="1">88 (45.8)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.01</td></tr><tr><td align="left" colspan="8" rowspan="1">Race category, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Black or African American</td><td align="left" colspan="1" rowspan="1">6 (2.9)</td><td align="left" colspan="1" rowspan="1">241 (16.7)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.48</td><td align="left" colspan="1" rowspan="1">38 (19.1)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.56</td><td align="left" colspan="1" rowspan="1">6 (2.8)</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not reported/other</td><td align="left" colspan="1" rowspan="1">45 (21.6)</td><td align="left" colspan="1" rowspan="1">269 (18.6)</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">38 (19.1)</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">42 (21.7)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;White</td><td align="left" colspan="1" rowspan="1">157 (75.5)</td><td align="left" colspan="1" rowspan="1">935 (64.7)</td><td align="left" colspan="1" rowspan="1">0.24</td><td align="left" colspan="1" rowspan="1">123 (61.8)</td><td align="left" colspan="1" rowspan="1">0.30</td><td align="left" colspan="1" rowspan="1">145 (75.5)</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">116 (55.8)</td><td align="left" colspan="1" rowspan="1">786 (54.4)</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">105 (52.7)</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">108 (55.8)</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">92 (44.2)</td><td align="left" colspan="1" rowspan="1">659 (45.6)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">94 (47.3)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.06</td><td align="left" colspan="1" rowspan="1">85 (44.2)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.00</td></tr><tr><td align="left" colspan="8" rowspan="1">Type of MM, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IgG</td><td align="left" colspan="1" rowspan="1">113 (54.3)</td><td align="left" colspan="1" rowspan="1">870 (60.2)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.12</td><td align="left" colspan="1" rowspan="1">125 (62.7)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.17</td><td align="left" colspan="1" rowspan="1">106 (55.2)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Light chain</td><td align="left" colspan="1" rowspan="1">47 (22.6)</td><td align="left" colspan="1" rowspan="1">228 (15.8)</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">24 (11.9)</td><td align="left" colspan="1" rowspan="1">0.27</td><td align="left" colspan="1" rowspan="1">39 (20.2)</td><td char="." align="char" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other</td><td align="left" colspan="1" rowspan="1">48 (23.1)</td><td align="left" colspan="1" rowspan="1">347 (24.0)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.02</td><td align="left" colspan="1" rowspan="1">50 (25.4)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.05</td><td align="left" colspan="1" rowspan="1">47 (24.6)</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#8201;0.04</td></tr></tbody></table><table-wrap-foot><p>The base case analysis adjusted for refractory status, time to progression on last regimen, cytogenetic risk, ISS stage, number of prior LOT, years since MM diagnosis, age, and hemoglobin. The fully adjusted analysis adjusted for all variables in the base case, plus prior stem cell transplant, ECOG PS, race, sex, and type of MM</p><p><italic toggle="yes">Cilta-cel</italic> ciltacabtagene autoleucel, <italic toggle="yes">ECOG PS</italic> Eastern Cooperative Oncology Group performance status, <italic toggle="yes">ESS</italic> effective sample size, <italic toggle="yes">IgG</italic> immunoglobulin&#160;G, <italic toggle="yes">IPTW</italic> inverse probability of treatment weighting, <italic toggle="yes">ISS</italic> International Staging System, <italic toggle="yes">LOT</italic> line of therapy, <italic toggle="yes">MM</italic> multiple myeloma, <italic toggle="yes">PI</italic> proteasome inhibitor, <italic toggle="yes">RW</italic> real-world, <italic toggle="yes">SMD</italic> standardized mean difference</p><p><sup>a</sup>1445 eligible LOT corresponding to 932 patients</p><p><sup>b</sup>Weighted patient numbers were rounded to whole numbers</p><p><sup>c</sup>In the RW cohort, high-risk cytogenetics included any of the following: del17p, t(4;14), or t(14;16). In the CARTITUDE-4 cilta-cel cohort, high-risk cytogenetics included any of the following: del17p, t(4;14), t(14;16), or gain/amp(1q)</p></table-wrap-foot></table-wrap></p><p id="Par25">After reweighting, baseline characteristics were balanced between the two cohorts (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Most SMD values were&#8201;&lt;&#8201;0.10, with the maximum value of 0.10 in the base case analysis and 0.13 in the fully adjusted analysis (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>; Supplemental Fig.&#160;<xref rid="MOESM1" ref-type="media">S1</xref>).</p></sec><sec id="Sec9"><title>Treatment Regimens Received in RW Clinical Practice</title><p id="Par26">In the RW cohort from the Flatiron database, across all eligible LOT, more than 50 treatment regimens were prescribed (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The most commonly prescribed treatment regimens were anti-CD38-based regimens, including DPd (16.0%), daratumumab monotherapy (8.2%), DKd (7.5%), DVd (daratumumab, bortezomib, and dexamethasone; 6.8%), DRd (daratumumab, lenalidomide, and dexamethasone; 1.8%), and Isa-Kd (isatuximab, carfilzomib, and dexamethasone; 1.5%). Of the 1445 eligible LOT, 17.7% were other drug combinations (i.e., all drugs not recommended as regimens for the treatment of MM by the NCCN, which may include any PI, IMiD, anti-CD38 monoclonal antibody, melphalan, cyclophosphamide, or selinexor).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Treatment regimens in the RW cohort in&#8201;&#8805;&#8201;1% of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Treatment regimen, <italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1445</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Other drug combination<sup>a</sup></td><td align="left" colspan="1" rowspan="1">256 (17.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">DPd</td><td align="left" colspan="1" rowspan="1">231 (16.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">120 (8.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Daratumumab monotherapy</td><td align="left" colspan="1" rowspan="1">118 (8.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">DKd</td><td align="left" colspan="1" rowspan="1">108 (7.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">DVd</td><td align="left" colspan="1" rowspan="1">98 (6.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">KPd</td><td align="left" colspan="1" rowspan="1">64 (4.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pd</td><td align="left" colspan="1" rowspan="1">57 (3.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Kd</td><td align="left" colspan="1" rowspan="1">43 (3.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Clinical trial<sup>b</sup></td><td align="left" colspan="1" rowspan="1">39 (2.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">CyKd</td><td align="left" colspan="1" rowspan="1">39 (2.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rd</td><td align="left" colspan="1" rowspan="1">34 (2.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">EloPd</td><td align="left" colspan="1" rowspan="1">31 (2.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Vd</td><td align="left" colspan="1" rowspan="1">27 (1.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">DRd</td><td align="left" colspan="1" rowspan="1">26 (1.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">PVd</td><td align="left" colspan="1" rowspan="1">22 (1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">CyVd</td><td align="left" colspan="1" rowspan="1">21 (1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">IsaKd</td><td align="left" colspan="1" rowspan="1">21 (1.5)</td></tr></tbody></table><table-wrap-foot><p>Percentages are calculated with the number of eligible lines of therapy in the all-treated analysis set as denominator (<italic toggle="yes">N</italic>&#8201;=&#8201;1445). Patients can be counted in more than 1 regimen or combination if they have received more than 1 combination in their treatment before progression or death</p><p><italic toggle="yes">Cy</italic> cyclophosphamide, <italic toggle="yes">d</italic> dexamethasone, <italic toggle="yes">D</italic> daratumumab, <italic toggle="yes">Elo</italic> elotuzumab, <italic toggle="yes">IMiD</italic> immunomodulatory drug, <italic toggle="yes">Isa</italic> isatuximab, <italic toggle="yes">K</italic> carfilzomib, <italic toggle="yes">MM</italic> multiple myeloma, <italic toggle="yes">NCCN</italic> National Comprehensive Cancer Network, <italic toggle="yes">P</italic> pomalidomide, <italic toggle="yes">PI</italic> proteasome inhibitor, <italic toggle="yes">R</italic> lenalidomide, <italic toggle="yes">V</italic> bortezomib</p><p><sup>a</sup>Included all drugs not recommended as regimens for the treatment of MM by NCCN, which may include any PI, IMiD, anti-CD38 monoclonal antibody, melphalan, cyclophosphamide, or selinexor</p><p><sup>b</sup>Details on the specific drug(s) being used in the context of a clinical trial were unavailable in the Flatiron Health database</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Comparative Analysis of Efficacy Outcomes</title><p id="Par27">In unadjusted analysis, patients in the cilta-cel cohort from CARTITUDE-4 showed significantly longer PFS (median not reached [NR] vs 8.1&#160;months; HR 0.32 [95%&#160;CI 0.25&#8211;0.40), RW-PFS (median NR vs 8.1&#160;months; HR 0.32 [95%&#160;CI 0.26&#8211;0.40]), TTNT (median NR vs 9.9&#160;months; HR 0.35 [95%&#160;CI 0.28&#8211;0.43]), and OS (median NR vs 45.3&#160;months; HR 0.60 [95%&#160;CI 0.43&#8211;0.82]) compared with the RW cohort (IPTW, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001 for all) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). For the cilta-cel cohort, the estimated 24- and 30-month OS rates were 79% and 76%; for the RW cohort, the unweighted 24- and 30-month OS rates were 70% and 66%, and weighted 24- and 30-month OS rates were 70% and 65%, respectively.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>IPTW base case analysis and fully adjusted analysis results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Outcome/Analysis</th><th align="left" colspan="3" rowspan="1">CARTITUDE-4 vs RW cohort</th></tr><tr><th align="left" colspan="1" rowspan="1">Median, months</th><th align="left" colspan="1" rowspan="1">HR (95%&#160;CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unadjusted</td><td align="left" colspan="1" rowspan="1">NR vs 8.1</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.32 (0.25&#8211;0.40)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Base case analysis</td><td align="left" colspan="1" rowspan="1">NR vs 8.2</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.29 (0.22&#8211;0.36)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fully adjusted analysis</td><td align="left" colspan="1" rowspan="1">NR vs 8.3</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.28 (0.22&#8211;0.38)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">RW-PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unadjusted</td><td align="left" colspan="1" rowspan="1">NR vs 8.1</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.32 (0.26&#8211;0.40)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Base case analysis</td><td align="left" colspan="1" rowspan="1">NR vs 8.2</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.29 (0.23&#8211;0.37)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fully adjusted analysis</td><td align="left" colspan="1" rowspan="1">NR vs 8.3</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.29 (0.22&#8211;0.38)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">TTNT</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unadjusted</td><td align="left" colspan="1" rowspan="1">NR vs 9.9</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.35 (0.28&#8211;0.43)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Base case analysis</td><td align="left" colspan="1" rowspan="1">NR vs 9.4</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.32 (0.25&#8211;0.41)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fully adjusted analysis</td><td align="left" colspan="1" rowspan="1">NR vs 9.9</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.31 (0.23&#8211;0.40)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">OS</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unadjusted</td><td align="left" colspan="1" rowspan="1">NR vs 45.3</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.60 (0.43&#8211;0.82)</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Base case analysis</td><td align="left" colspan="1" rowspan="1">NR vs 45.4</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.59 (0.41&#8211;0.84)</td><td char="." align="char" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fully adjusted analysis</td><td align="left" colspan="1" rowspan="1">NR vs NR</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.78 (0.52&#8211;1.16)</td><td char="." align="char" colspan="1" rowspan="1">0.222</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">HR</italic> hazard ratio, <italic toggle="yes">IPTW</italic> inverse probability of treatment weighting, <italic toggle="yes">NR</italic> not reached, <italic toggle="yes">OS</italic> overall survival, <italic toggle="yes">PFS</italic> progression-free survival, <italic toggle="yes">RW</italic> real-world, <italic toggle="yes">TTNT</italic> time to next treatment</p></table-wrap-foot></table-wrap></p><p id="Par28">The base case analysis showed similar results, i.e., significantly improved outcomes were found in the cilta-cel cohort compared with the RW cohort (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>, Supplemental Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). After adjustment, for patients in the cilta-cel cohort from CARTITUDE-4 compared with patients in the RW cohort, PFS (median NR vs 8.2&#160;months; HR 0.29 [95%&#160;CI 0.22&#8211;0.36]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Supplemental Fig. <xref rid="MOESM1" ref-type="media">S2</xref>), RW-PFS (median NR vs 8.2&#160;months; HR 0.29 [95%&#160;CI 0.23&#8211;0.37]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a), TTNT (median NR vs 9.4&#160;months; HR 0.32 [95%&#160;CI 0.25&#8211;0.41]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a), and OS were significantly longer (median NR vs 45.4&#160;months; HR 0.59 [95%&#160;CI 0.41&#8211;0.84]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a). All <italic toggle="yes">p</italic>&#160;values were based on IPTW.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Adjusted (ATT-weighted) Kaplan&#8211;Meier plots of real-world progression-free survival for <bold>a</bold> base case analysis and <bold>b</bold> fully adjusted analysis. <italic toggle="yes">ATT</italic> average treatment effect in the treated, <italic toggle="yes">cilta-cel</italic> ciltacabtagene autoleucel</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12325_2025_3308_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Adjusted (ATT-weighted) Kaplan&#8211;Meier plots of time to next treatment for <bold>a</bold> base case analysis and <bold>b</bold> fully adjusted analysis. <italic toggle="yes">ATT</italic> average treatment effect in the treated, <italic toggle="yes">cilta-cel</italic> ciltacabtagene autoleucel</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12325_2025_3308_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Adjusted (ATT-weighted) Kaplan&#8211;Meier plots of overall survival for <bold>a</bold> base case analysis and <bold>b</bold> fully adjusted analysis. <italic toggle="yes">ATT</italic> average treatment effect in the treated, <italic toggle="yes">cilta-cel</italic> ciltacabtagene autoleucel</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12325_2025_3308_Fig4_HTML.jpg"/></fig></p><p id="Par29">Overall, results in the fully adjusted analysis were consistent with the base case analysis (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>, Supplemental Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). After adjustment, in patients in the cilta-cel cohort from CARTITUDE-4 compared with patients in the RW cohort, PFS (median NR vs 8.3&#160;months; HR 0.28 [95%&#160;CI 0.22&#8211;0.38]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Supplemental Fig. <xref rid="MOESM1" ref-type="media">S2</xref>), RW-PFS (median NR vs 8.3&#160;months; HR 0.29 [95%&#160;CI 0.22&#8211;0.38]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>b), and TTNT were significantly longer (median NR vs 9.9&#160;months; HR 0.31 [95%&#160;CI 0.23&#8211;0.40]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b). The OS was similar in patients in the cilta-cel cohort compared with patients in the RW cohort after adjustment (median NR in both cohorts; HR 0.78 [95%&#160;CI 0.52&#8211;1.16]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.222) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>b). All <italic toggle="yes">p</italic>&#160;values were based on IPTW.</p><p id="Par30">Sensitivity analyses using doubly robust and multivariable regression, as well as first patient case weighting, yielded similar results (Supplemental Table&#160;<xref rid="MOESM1" ref-type="media">S3</xref> and <xref rid="MOESM1" ref-type="media">S4</xref>).</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p id="Par31">This ITC study compared cilta-cel from the CARTITUDE-4 study with RW physician&#8217;s choice of treatment from the Flatiron Health MM cohort, using propensity scores to align patient populations. Cilta-cel demonstrated superiority over the RW cohort for all outcomes, with similar favorable results in the fully adjusted analysis. Results from the base case analysis showed that cilta-cel reduced the risk of progression or death by 71%, reduced the risk of progression, initiating next treatment, or death by 71%, reduced the risk of initiation of the next LOT or death by 68%, and reduced the risk of death by 41% compared with the RW cohort. Results were consistent with the base case and fully adjusted analyses when doubly robust or multivariable regression were used in place of IPTW. Overall, the robustness and consistency of these findings across all analyses suggest that cilta-cel represents a promising treatment option for patients with MM in earlier LOT who are refractory to lenalidomide.</p><p id="Par32">The strength of the control arm used in the present ITC study provided additional confidence in the findings. It captured the most recent innovative regimens available in clinical practice, as this analysis included patients treated from 2020 to 2024. In the unadjusted RW cohort, the median PFS, RW-PFS, TTNT, and OS were 8.1, 8.1, 9.9, and 45.3&#160;months, respectively. Compared with the present analysis, similar results for median PFS (10.7&#160;months) but not median OS (23.8&#160;months) were observed in a RW, retrospective study in patients who were lenalidomide refractory [<xref ref-type="bibr" rid="CR30">30</xref>]. In another RW cohort [<xref ref-type="bibr" rid="CR31">31</xref>], median OS (21.5&#160;months) was also lower than that observed in our RW cohort in lenalidomide-refractory patients with 1&#8211;3 prior LOT. However, considering that CARTITUDE-4 is an international study with study centers in the USA, Europe, Asia, and Australia, whereas the Flatiron data are from the USA only, the comparison with the other regions of the world may be different.</p><p id="Par33">The current analysis was conducted in patients with lenalidomide-refractory MM. In CARTITUDE-4, the refractory status was defined prospectively using trial criteria, whereas in the RW cohort, it relied on retrospective EHR-based proxies, which might lead to overestimated refractoriness. Further, over 50 distinct treatment regimens were included in the RW cohort and patient numbers in various treatment groups (e.g., anti-CD38-based regimens or non-CD38-based therapies) were limited, resulting in insufficient data to carry out meaningful subgroup or stratified analysis. Limitations of the present analysis included the potential for residual confounding, which is not uncommon in a nonrandomized study. However, the availability of individual patient-level data from both cohorts enabled adjustment for imbalances in important prognostic factors. Although the process ensured key clinical factors were balanced between the two patient populations (i.e., one included participants in the international trial CARTITUDE-4 who received cilta-cel, the other included patients who received care from US academic and community cancer centers), total plasmacytomas and LDH levels were unavailable a priori in the de-identified database for the RW cohort. In addition, the missingness in the cytogenetic risk between the two data sources may present different risk mixes, and the actual distributions of the high-risk and standard-risk cytogenetics in each cohort were unknown. Matching on missing cytogenetic data was incomplete, albeit the same definition of high-risk cytogenetics was applied to both the cilta-cel and the RW cohorts. An external control arm from a RW data source such as the Flatiron Health database can be used to estimate the relative therapeutic effects of cilta-cel versus RW physician&#8217;s choice of treatment in clinical practice; however, estimates may be biased if there are significant differences in baseline characteristics between the patient populations. These variations in baseline characteristics can be mitigated by indirect, well-balanced analyses of nonrandomized populations across all variables potentially prognostic of outcomes. ITCs using IPTW methods are used to assess the benefits of a treatment relative to regimens used in clinical practice and ensure unbiased comparative effectiveness data that can assist physicians and payers in making decisions. IPTW methods are a robust and feasible approach due to the access of patient-level data. Another limitation is that information on response outcomes, such as overall and complete response rates, were unavailable for the RW cohort, which prevented comparative effectiveness analyses of these outcomes. Furthermore, monitoring of patients in RW databases is less rigorous and subject to greater variation than in clinical trials, where patients are regularly monitored. Lastly, PFS data quality may also be a limitation, as progression data such as bone marrow plasma cells, bone lesions, and the size of soft-tissue plasmacytomas were more likely to be missing for patients in the RW cohort than in CARTITUDE-4. To avoid underestimating progression in the RW cohort, we assessed RW-PFS, which accounts for TTNT. Results were consistent with the PFS comparison. OS data quality is not expected to be affected, as methods to assess OS have been validated for the de-identified database [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusion</title><p id="Par34">In our analyses, ITC methods were used to compare patient-level data from the CARTITUDE-4 clinical study with an external control arm created from eligible patients with lenalidomide-refractory MM after 1&#8211;3 prior LOT who received RW treatment in a de-identified database. After adjusting for baseline characteristics, cilta-cel showed statistically significant superiority for PFS, RW-PFS, TTNT, and OS versus RW treatment. Sensitivity analyses supported the results of the base case analyses. On the basis of these results, cilta-cel provides superior clinical benefit compared with RW physician&#8217;s choice of conventional regimens, highlighting the value of cilta-cel as an effective therapy in patients with lenalidomide-refractory MM as early as first relapse.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12325_2025_3308_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 644 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Prior Presentation</bold>: This manuscript is based on work that was previously presented at the 2024 European Haematology Association Hybrid Congress; June 13&#8211;16, 2024; Madrid, Spain, and online. Touzeau C, et al. Comparative effectiveness of ciltacabtagene autoleucel from the CARTITUDE-4 trial vs real-world physician&#8217;s choice of therapy from the Flatiron Registry in lenalidomide-refractory multiple myeloma (#P967).</p></fn><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the patients who volunteered to participate in the study, their families and caregivers, the physicians and nurses who cared for the patients and supported this clinical trial, staff members at the 81 study sites in the United States, Europe, Asia, and Australia who enrolled patients, and staff members who were involved in data collection and analysis.</p><sec id="d33e1970"><title>Medical Writing/Editorial Assistance</title><p id="Par35">Medical writing support was provided by Alana Dorfstatter, PharmD, of Eloquent, part of Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, and funded by Johnson &amp; Johnson.</p></sec></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Cyrille Touzeau, Brea Lipe, Abdullah M Khan, Binod Dhakal, Sandhya Nair, Jianming He, Jo&#227;o Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noem&#237; Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, and Surbhi Sidana contributed to the study conception and design, material preparation, and data collection. Cyrille Touzeau, Brea Lipe, Abdullah M Khan, Binod Dhakal, Sandhya Nair, Jianming He, Jo&#227;o Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noem&#237; Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, and Surbhi Sidana performed the analysis and contributed to the development of the first and subsequent drafts of the manuscript. Cyrille Touzeau, Brea Lipe, Abdullah M Khan, Binod Dhakal, Sandhya Nair, Jianming He, Jo&#227;o Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noem&#237; Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, and Surbhi Sidana read and approved the final manuscript. Cyrille Touzeau, Brea Lipe, Abdullah M Khan, Binod Dhakal, Sandhya Nair, Jianming He, Jo&#227;o Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noem&#237; Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, and Surbhi Sidana meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study (ClinicalTrials.gov identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04181827">NCT04181827</ext-link>) was funded by Johnson &amp; Johnson and Legend Biotech USA Inc. Funding for the journal&#8217;s Rapid Service and Open Access Fees was provided by Johnson &amp; Johnson and Legend Biotech USA Inc.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data sharing policy of Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.janssen.com/clinical-trials/transparency">https://www.janssen.com/clinical-trials/transparency</ext-link>. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://yoda.yale.edu">http://yoda.yale.edu</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par36">Cyrille Touzeau: Honoraria &#8211; AbbVie, Amgen, Bristol Myers Squibb/Celgene, Janssen, Pfizer, Sanofi, Takeda; consulting or advisory role &#8211; AbbVie, Amgen, Bristol Myers Squibb/Celgene, Janssen, Pfizer, Takeda; research funding &#8211; Sanofi (Inst); travel, accommodations, expenses &#8211; Johnson &amp; Johnson/Janssen, Pfizer, Sanofi. Brea Lipe: Consulting or advisory role &#8211; AbbVie, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi; research funding &#8211; Amgen. Abdullah M Khan: Speakers&#8217; bureau &#8211; Amgen, Sanofi; research funding &#8211; Bristol Myers Squibb, Sanofi; travel, accommodations, expenses &#8211; Bristol Myers Squibb. Binod Dhakal: Consulting or advisory role &#8211; Amgen, Arcellx, Genentech/Roche, GlaxoSmithKline, Janssen Oncology, Natera, Pfizer, Sanofi, Pfizer, Takeda; speakers bureau &#8211; Janssen Oncology; honoraria &#8211; Celgene, GlaxoSmithKline, Karyopharm Therapeutics, Sanofi; research funding &#8211; Amgen (Inst), Arcellx (Inst), CARsgen Therapeutics (Inst), Bristol Myers Squibb/Celgene (Inst), GlaxoSmithKline, Janssen Oncology (Inst), Sanofi (Inst). Man Zhao: Employment &#8211; Haisco Pharmaceutical (I), IQVIA, Janssen; research funding &#8211; Haisco Pharmaceutical (I); patents, royalties, other intellectual property &#8211; Haisco Pharmaceutical (I). Xavier Leleu: Honoraria &#8211; Bristol Myers Squibb, Takeda. Noem&#237; Puig: Honoraria &#8211; Amgen, Celgene, Janssen, Pfizer, Sanofi, Takeda, The Binding Site; consulting or advisory role &#8211; Amgen, Celgene, Janssen, Pfizer, Sanofi, Takeda, The Binding Site; speakers bureau &#8211; Celgene; research funding &#8211; Amgen, Celgene, Janssen, Pfizer, Takeda; travel, accommodations, expenses &#8211; Amgen, Celgene, Janssen, Pfizer, Takeda, The Binding Site. Dominik Dytfeld: Honoraria &#8211; Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer; consulting or advisory role &#8211; Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer; research funding &#8211; Bristol Myers Squibb, Janssen; travel, accommodations, expenses &#8211; Amgen, Janssen, Bristol Myers Squibb, Pfizer. Elena Zamagni: Honoraria and advisory role &#8211; Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini-Stemline, Oncopeptides, Pfizer, Sanofi. Katja Weisel: Honoraria &#8211; AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen (Inst), Janssen-Cilag, Karyopharm Therapeutics, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline Therapeutics, Takeda; consulting or advisory role &#8211; Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Menarini, Oncopeptides, Roche, Sanofi, Takeda; research funding &#8211; AbbVie (Inst), Amgen (Inst), Bristol Myers Squibb/Celgene (Inst), Celgene (Inst), GlaxoSmithKline (Inst), Janssen-Cilag (Inst), Sanofi (Inst); travel, accommodations, expenses &#8211; Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Menarini, Takeda. Lionel Karlin: Honoraria &#8211; AbbVie, Amgen, Celgene, Johnson &amp; Johnson, Takeda; consulting or advisory role &#8211; Amgen, Celgene, Johnson &amp; Johnson, Takeda; travel, accommodations, expenses &#8211; Amgen, Johnson &amp; Johnson. Michel Delforge: Honoraria &#8211; Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson &amp; Johnson; consulting or advisory role &#8211; Johnson &amp; Johnson. Paolo Corradini: Honoraria &#8211; AbbVie, Amgen, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Sanofi, Takeda; consulting or advisory role &#8211; AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda. Roberto Mina: Honoraria &#8211; AbbVie, Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, Sanofi; consulting or advisory role &#8211; Bristol Myers Squibb, GlaxoSmithKline, Janssen-Cilag EMEA, Janssen Pharmaceuticals, Pfizer, Takeda. Wilfried Roeloffzen: Honoraria &#8211; Amgen (Inst), Fondation Sanofi Espoir (Inst), Janssen Biotech (Inst); consulting or advisory role &#8211; Bristol Myers Squibb (Inst); travel, accommodations, expenses &#8211; AbbVie. Surbhi Sidana: Consulting or advisory role &#8211; AbbVie, BiolineRx, Bristol Myers Squibb/Celgene, Genentech/Roche, Janssen, Kite/Gilead, Legend Biotech, Pfizer, Regeneron, Sanofi; research funding &#8211; AbbVie (Inst), Allogene Therapeutics (Inst), Bristol Myers Squibb/Celgene (Inst), Janssen (Inst), Magenta Therapeutics (Inst), Novartis (Inst). Sandhya Nair, Seina Lee, Carolina Lonardi, and Diana Chen: Employment &#8211; Johnson &amp; Johnson. Jianming He, Jo&#227;o Mendes, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, and Tzu-min Yeh: Employment &#8211; Johnson &amp; Johnson; stock and other ownership interests &#8211; Johnson &amp; Johnson.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par37">CARTITUDE-4 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. The independent ethics committee or institutional review board at each site approved the protocol (Supplemental Table&#160;<xref rid="MOESM1" ref-type="media">S1</xref>). All patients provided written informed consent.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term follow-up on overall survival from the MM-009 and MM-010 phase&#160;III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.147</pub-id><pub-id pub-id-type="pmid">19626046</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase&#160;III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147&#8211;52.<pub-id pub-id-type="pmid">19626046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2009.147</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase&#160;3, open-label, multicentre study</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00464-7</pub-id><pub-id pub-id-type="pmid">26671818</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase&#160;3, open-label, multicentre study. Lancet Oncol. 2016;17:27&#8211;38.<pub-id pub-id-type="pmid">26671818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(15)00464-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miguel</surname><given-names>JS</given-names></name><name name-style="western"><surname>Weisel</surname><given-names>K</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase&#160;3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70380-2</pub-id><pub-id pub-id-type="pmid">24007748</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase&#160;3 trial. Lancet Oncol. 2013;14:1055&#8211;66.<pub-id pub-id-type="pmid">24007748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(13)70380-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlowski</surname><given-names>RZ</given-names></name><name name-style="western"><surname>Nagler</surname><given-names>A</given-names></name><name name-style="western"><surname>Sonneveld</surname><given-names>P</given-names></name><etal/></person-group><article-title>Randomized phase&#160;III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>3892</fpage><lpage>3901</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.10.5460</pub-id><pub-id pub-id-type="pmid">17679727</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase&#160;III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892&#8211;901.<pub-id pub-id-type="pmid">17679727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2006.10.5460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raab</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cavo</surname><given-names>M</given-names></name><name name-style="western"><surname>Delforge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multiple myeloma: practice patterns across Europe</article-title><source>Br J Haematol</source><year>2016</year><volume>175</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/bjh.14193</pub-id><pub-id pub-id-type="pmid">27291397</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66&#8211;76.<pub-id pub-id-type="pmid">27291397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.14193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San-Miguel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hungria</surname><given-names>VT</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase&#160;3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70440-1</pub-id><pub-id pub-id-type="pmid">25242045</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase&#160;3 trial. Lancet Oncol. 2014;15:1195&#8211;206.<pub-id pub-id-type="pmid">25242045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)70440-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Nahi</surname><given-names>H</given-names></name><name name-style="western"><surname>Plesner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase&#160;2 GEN501 and SIRIUS trials</article-title><source>Lancet Haematol</source><year>2020</year><volume>7</volume><fpage>e447</fpage><lpage>e455</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(20)30081-8</pub-id><pub-id pub-id-type="pmid">32470437</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase&#160;2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7:e447&#8211;55.<pub-id pub-id-type="pmid">32470437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3026(20)30081-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhakal</surname><given-names>B</given-names></name><name name-style="western"><surname>Einsele</surname><given-names>H</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>R</given-names></name><etal/></person-group><article-title>P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database</article-title><source>Clin Lymphoma Myeloma Leuk</source><year>2022</year><volume>22</volume><fpage>S167</fpage><pub-id pub-id-type="doi">10.1016/S2152-2650(22)00570-5</pub-id><pub-id pub-id-type="pmid">39966019</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dhakal B, Einsele H, Potluri R, et al. P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database. Clin Lymphoma Myeloma Leuk. 2022;22:S167.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clml.2025.01.009</pub-id><pub-id pub-id-type="pmid">39966019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhakal</surname><given-names>B</given-names></name><name name-style="western"><surname>Einsele</surname><given-names>H</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>R</given-names></name><etal/></person-group><article-title>P899: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed/refractory multiple myeloma from the optum database</article-title><source>HemaSphere</source><year>2022</year><volume>6</volume><fpage>790</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1097/01.HS9.0000846468.64341.f1</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Dhakal B, Einsele H, Potluri R, et al. P899: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed/refractory multiple myeloma from the optum database. HemaSphere. 2022;6:790&#8211;1.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Terpos</surname><given-names>E</given-names></name><etal/></person-group><article-title>Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Hemasphere</source><year>2021</year><volume>5</volume><fpage>e528</fpage><pub-id pub-id-type="pmid">33554050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HS9.0000000000000528</pub-id><pub-id pub-id-type="pmcid">PMC7861652</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528.<pub-id pub-id-type="pmid">33554050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HS9.0000000000000528</pub-id><pub-id pub-id-type="pmcid">PMC7861652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Lobato</surname><given-names>LG</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A</given-names></name><name name-style="western"><surname>Fern&#225;ndez de Larrea</surname><given-names>C</given-names></name><etal/></person-group><article-title>Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period</article-title><source>Br J Haematol</source><year>2022</year><volume>196</volume><fpage>649</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1111/bjh.17888</pub-id><pub-id pub-id-type="pmid">34622447</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Rodriguez-Lobato LG, Pereira A, Fern&#225;ndez de Larrea C, et al. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022;196:649&#8211;59.<pub-id pub-id-type="pmid">34622447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.17888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Donk</surname><given-names>N</given-names></name></person-group><article-title>Sequencing multiple myeloma therapies with and after antibody therapies</article-title><source>Hematology Am Soc Hematol Educ Program</source><year>2020</year><volume>2020</volume><fpage>248</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1182/hematology.2020000109</pub-id><pub-id pub-id-type="pmid">33275724</pub-id><pub-id pub-id-type="pmcid">PMC7727523</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program. 2020;2020:248&#8211;58.<pub-id pub-id-type="pmid">33275724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/hematology.2020000109</pub-id><pub-id pub-id-type="pmcid">PMC7727523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">REVLIMID (lenalidomide) [Prescribing information]. Summit, NJ. Celgene Corporation, 2013.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Arriba de la Fuente</surname><given-names>F</given-names></name><name name-style="western"><surname>Montes Gais&#225;n</surname><given-names>C</given-names></name><name name-style="western"><surname>de la Rubia</surname><given-names>Comos J</given-names></name></person-group><article-title>How to manage patients with lenalidomide-refractory multiple myeloma</article-title><source>Cancers (Basel)</source><year>2022</year><volume>15</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.3390/cancers15010155</pub-id><pub-id pub-id-type="pmid">36612152</pub-id><pub-id pub-id-type="pmcid">PMC9818178</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">de Arriba de la Fuente F, Montes Gais&#225;n C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel). 2022;15:155.<pub-id pub-id-type="pmid">36612152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15010155</pub-id><pub-id pub-id-type="pmcid">PMC9818178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulig</surname><given-names>P</given-names></name><name name-style="western"><surname>Milczarek</surname><given-names>S</given-names></name><name name-style="western"><surname>Bakinowska</surname><given-names>E</given-names></name><name name-style="western"><surname>Szalewska</surname><given-names>L</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>B</given-names></name><name name-style="western"><surname>Machalinski</surname><given-names>B</given-names></name></person-group><article-title>Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><fpage>963</fpage><pub-id pub-id-type="doi">10.3390/cancers15030963</pub-id><pub-id pub-id-type="pmid">36765919</pub-id><pub-id pub-id-type="pmcid">PMC9913106</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machalinski B. Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives. Cancers (Basel). 2023;15:963.<pub-id pub-id-type="pmid">36765919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15030963</pub-id><pub-id pub-id-type="pmcid">PMC9913106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) for Multiple Myeloma V.1.2025. &#169; National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 31, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>SK</given-names></name><name name-style="western"><surname>San Miguel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>e105</fpage><lpage>e118</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30756-7</pub-id><pub-id pub-id-type="pmid">33662288</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105&#8211;18.<pub-id pub-id-type="pmid">33662288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(20)30756-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San-Miguel</surname><given-names>J</given-names></name><name name-style="western"><surname>Dhakal</surname><given-names>B</given-names></name><name name-style="western"><surname>Yong</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cilta-cel or standard care in lenalidomide-refractory multiple myeloma</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><fpage>335</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2303379</pub-id><pub-id pub-id-type="pmid">37272512</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335&#8211;47.<pub-id pub-id-type="pmid">37272512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2303379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Mateos M-V, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase&#160;3 CARTITUDE-4 study update. Presented at IMS; September 25&#8211;28, 2024; Rio de Janeiro, Brazil.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Janssen Biotech Inc. CARVYKTI&#174; (ciltacabtagene autoleucel) suspension for intravenous infusion [Prescribing information]. Horsham, PA: Janssen Biotech, Inc., 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/156560/download?attachment">https://www.fda.gov/media/156560/download?attachment</ext-link>. Accessed April 1, 2025.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhakal</surname><given-names>B</given-names></name><name name-style="western"><surname>Einsele</surname><given-names>H</given-names></name><name name-style="western"><surname>Schecter</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1&#8211;3 prior lines): Flatiron database</article-title><source>Blood Adv</source><year>2024</year><volume>8</volume><fpage>5062</fpage><lpage>5071</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2024012640</pub-id><pub-id pub-id-type="pmid">39110988</pub-id><pub-id pub-id-type="pmcid">PMC11459902</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dhakal B, Einsele H, Schecter JM, et al. Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1&#8211;3 prior lines): Flatiron database. Blood Adv. 2024;8:5062&#8211;71.<pub-id pub-id-type="pmid">39110988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2024012640</pub-id><pub-id pub-id-type="pmcid">PMC11459902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Mojebi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>D</given-names></name><etal/></person-group><article-title>Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma</article-title><source>J Comp Eff Res</source><year>2022</year><volume>11</volume><fpage>737</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.2217/cer-2022-0045</pub-id><pub-id pub-id-type="pmid">35485211</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Shah N, Mojebi A, Ayers D, et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022;11:737&#8211;49.<pub-id pub-id-type="pmid">35485211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/cer-2022-0045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisel</surname><given-names>K</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>A</given-names></name><name name-style="western"><surname>Schecter</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma</article-title><source>Clin Lymphoma Myeloma Leuk</source><year>2022</year><volume>22</volume><fpage>690</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/j.clml.2022.04.025</pub-id><pub-id pub-id-type="pmid">35764490</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Weisel K, Krishnan A, Schecter JM, et al. Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:690&#8211;701.<pub-id pub-id-type="pmid">35764490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clml.2022.04.025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>T</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yong</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician&#8217;s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma</article-title><source>EJHaem</source><year>2022</year><volume>3</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1002/jha2.312</pub-id><pub-id pub-id-type="pmid">35846215</pub-id><pub-id pub-id-type="pmcid">PMC9175662</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Martin T, Krishnan A, Yong K, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician&#8217;s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem. 2022;3:97&#8211;108.<pub-id pub-id-type="pmid">35846215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jha2.312</pub-id><pub-id pub-id-type="pmcid">PMC9175662</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. 10.1101/2020.03.16.20037143.</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajkumar</surname><given-names>SV</given-names></name><name name-style="western"><surname>Harousseau</surname><given-names>JL</given-names></name><name name-style="western"><surname>Durie</surname><given-names>B</given-names></name><etal/></person-group><article-title>Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>4691</fpage><lpage>4695</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-10-299487</pub-id><pub-id pub-id-type="pmid">21292775</pub-id><pub-id pub-id-type="pmcid">PMC3710442</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691&#8211;5.<pub-id pub-id-type="pmid">21292775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-10-299487</pub-id><pub-id pub-id-type="pmcid">PMC3710442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usmani</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Analysis of real-world data on overall survival in multiple myeloma patients with &#8805;3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD</article-title><source>Oncologist</source><year>2016</year><volume>21</volume><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0104</pub-id><pub-id pub-id-type="pmid">27486203</pub-id><pub-id pub-id-type="pmcid">PMC5189616</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with &#8805;3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355&#8211;61.<pub-id pub-id-type="pmid">27486203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2016-0104</pub-id><pub-id pub-id-type="pmcid">PMC5189616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austin</surname><given-names>PC</given-names></name></person-group><article-title>Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples</article-title><source>Stat Med</source><year>2009</year><volume>28</volume><fpage>3083</fpage><lpage>3107</lpage><pub-id pub-id-type="doi">10.1002/sim.3697</pub-id><pub-id pub-id-type="pmid">19757444</pub-id><pub-id pub-id-type="pmcid">PMC3472075</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#8211;107.<pub-id pub-id-type="pmid">19757444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.3697</pub-id><pub-id pub-id-type="pmcid">PMC3472075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funk</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Westreich</surname><given-names>D</given-names></name><name name-style="western"><surname>Wiesen</surname><given-names>C</given-names></name><name name-style="western"><surname>St&#252;rmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Brookhart</surname><given-names>MA</given-names></name><name name-style="western"><surname>Davidian</surname><given-names>M</given-names></name></person-group><article-title>Doubly robust estimation of causal effects</article-title><source>Am J Epidemiol</source><year>2011</year><volume>173</volume><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1093/aje/kwq439</pub-id><pub-id pub-id-type="pmid">21385832</pub-id><pub-id pub-id-type="pmcid">PMC3070495</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Funk MJ, Westreich D, Wiesen C, St&#252;rmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761&#8211;7.<pub-id pub-id-type="pmid">21385832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwq439</pub-id><pub-id pub-id-type="pmcid">PMC3070495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kastritis</surname><given-names>E</given-names></name><name name-style="western"><surname>Ntanasis-Stathopoulos</surname><given-names>I</given-names></name><name name-style="western"><surname>Theodorakakou</surname><given-names>F</given-names></name><etal/></person-group><article-title>Characteristics and outcomes of patients with relapsed/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in Greece</article-title><source>Clin Lymphoma Myeloma Leuk</source><year>2024</year><volume>24</volume><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.clml.2024.03.003</pub-id><pub-id pub-id-type="pmid">38616479</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, et al. Characteristics and outcomes of patients with relapsed/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in Greece. Clin Lymphoma Myeloma Leuk. 2024;24:468&#8211;77.<pub-id pub-id-type="pmid">38616479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clml.2024.03.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajek</surname><given-names>R</given-names></name><name name-style="western"><surname>Sliwka</surname><given-names>H</given-names></name><name name-style="western"><surname>Stork</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patient characteristics and survival outcomes of lenalidomide exposed non-refractory vs lenalidomide refractory multiple myeloma patients in the HONEUR Federated Data Network</article-title><source>Blood</source><year>2022</year><volume>140</volume><issue>Supplement 1</issue><fpage>7200</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1182/blood-2022-159401</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Hajek R, Sliwka H, Stork M, et al. Patient characteristics and survival outcomes of lenalidomide exposed non-refractory vs lenalidomide refractory multiple myeloma patients in the HONEUR Federated Data Network. Blood. 2022;140(Supplement 1):7200&#8211;2.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>MD</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>SD</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development and validation of a high-quality composite real-world mortality endpoint</article-title><source>Health Serv Res</source><year>2018</year><volume>53</volume><fpage>4460</fpage><lpage>4476</lpage><pub-id pub-id-type="doi">10.1111/1475-6773.12872</pub-id><pub-id pub-id-type="pmid">29756355</pub-id><pub-id pub-id-type="pmcid">PMC6232402</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Curtis MD, Griffith SD, Tucker M, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res. 2018;53:4460&#8211;76.<pub-id pub-id-type="pmid">29756355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1475-6773.12872</pub-id><pub-id pub-id-type="pmcid">PMC6232402</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>